spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  vertigo 

 HSMN NewsFeed - 29 Sep 2026
VertigoDx Secures FDA 510(k) Clearance for SmartVertigo(R) Point-of-Care Vestibular Diagnostic System
Diagnostics FDA
 HSMN NewsFeed - 29 Mar 2023
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 28 Oct 2020
Citrine Medicine Advances Efforts to Create the Very First Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix(R) (pitolisant)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Oct 2020
REYVOW(R) (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Sep 2020
REYVOW(TM) (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Jul 2020
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 18 Jun 2020
Almirall Announces FDA Approval Of Updated Label For Seysara(R) (Sarecycline) Tablets
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 3 Sep 2019
Strekin AG Secures Financing to Complete Development of STR001 in Sudden Sensorineural Hearing Loss and to Prepare NDA Filing in Europe
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Sep 2017
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Apr 2017
FDA Approves Radius Health’s TYMLOS(TM) (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Mar 2016
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jan 2016
Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jan 2016
Impax Receives Approval of EMVERM(TM) (mebendazole) Chewable Tablets, 100 mg
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Dec 2015
Antares Pharma Announces FDA Approval of Sumatriptan Injection USP
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Nov 2015
OticPharma Appoints Keith A. Katkin as Chairman of the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Nov 2015
Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere's Disease
Biopharmaceuticals
 HSMN NewsFeed - 15 Sep 2015
FDA Approves Octapharma’s NUWIQ for the Treatment of Adults and Children with Hemophilia
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Mar 2015
Mylan Launches Generic Antabuse(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 24 Apr 2014
Endo Acquires Rights to Sumavel(R) DosePro(R)
Biopharmaceuticals Drug Delivery Acquisitions
 HSMN NewsFeed - 30 Jan 2014
Chelsea Therapeutics Names Keith W. Schmidt Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 27 Jan 2014
Chelsea Therapeutics Announces Joseph G. Oliveto Named President and Chief Executive Officer, Director
Biopharmaceuticals Neurology Cardiology Personnel
 HSMN NewsFeed - 2 Jan 2014
Eisai Announces U.S. Availability of FYCOMPA(TM) (perampanel) CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA
 HSMN NewsFeed - 13 Jun 2011
Valeant and GlaxoSmithKline Announce U.S. FDA Approval of Potiga (ezogabine)
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jan 2011
Zogenix and Desitin Announce Marketing Approval for SUMAVEL(R) DosePro(TM) in Germany and the United Kingdom
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Oct 2010
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Feb 2010
Otonomy Receives FDA Clearance to Initiate Clinical Trial in Patients with Meniere's Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Dec 2009
FDA Accepts NDA Filing for Retigabine
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2009
Zogenix and Astellas Announce Data Published Showing the Benefits of SUMAVEL(TM) DosePro(TM) Needle-Free Delivery System
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 28 Sep 2009
Abbott to Acquire Solvay Pharmaceuticals Business
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 May 2009
AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
Biopharmaceuticals
 HSMN NewsFeed - 21 Oct 2008
Abbott's HUMIRA(R) (adalimumab) Data Shows Fistula Healing for Up to Three Years in Patients with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Sep 2008
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2008
Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2008
HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2008
New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Apr 2008
American Academy of Otolaryngology-Head and Neck Surgery Approves Policy Statement on Micropressure Therapy for Meniere's Disease
Devices
 HSMN NewsFeed - 3 Mar 2008
Endo Pharmaceuticals to Launch Three New Dosage Strengths of OPANA(R) ER
Biopharmaceuticals Pain Management FDA
 HSMN NewsFeed - 7 Feb 2008
Chelsea Therapeutics Begins Patient Dosing in Pivotal Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Dec 2007
New Phase III Trial Shows Positive Outcome of lacosamide in Patients with Diabetic Neuropathic Pain
Biopharmaceuticals
 HSMN NewsFeed - 27 Nov 2007
Valeant Pharmaceuticals Completes Enrollment of Second Pivotal Phase 3 Trial for Epilepsy Drug Retigabine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Nov 2007
FDA Accepts Chelsea Therapeutics' Investigational New Drug Application for Droxidopa
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Aug 2007
European Commission Grants Chelsea Therapeutics Two Orphan Medicinal Product Designations for Droxidopa
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Jul 2007
Tamiflu(R) 30 mg and 45 mg Capsules Approved by U.S. Food and Drug Administration
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jun 2007
Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 27 Apr 2007
Abbott's HUMIRA(R) (Adalimumab) Receives Positive Opinion from European Medicines Agency for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 9 Mar 2007
Roche Files Supplemental New Drug Application with U.S. Food & Drug Administration for Tamiflu(R) 30 mg and 45 mg Capsules
Biopharmaceuticals
 HSMN NewsFeed - 22 Feb 2007
Valeant Pharmaceuticals Files Investigational New Drug Application for Cesamet(R) in Cancer Chemotherapy-Induced Neuropathic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Feb 2007
Valeant Pharmaceuticals Acquires Rights to Nabilone in United Kingdom and Europe
Biopharmaceuticals
 HSMN NewsFeed - 25 Jan 2007
Valeant Pharmaceuticals Developing Intranasal Diazepam for the At-Home Treatment of Emergency Seizures
Biopharmaceuticals Drug Delivery Neurology
 HSMN NewsFeed - 3 Jan 2007
Study Offers Hope of Long-Term Vertigo Relief for Meniere's Disease Patients
Devices
 HSMN NewsFeed - 21 Nov 2006
Par Pharmaceutical Begins Shipment of Generic TOPROL-XL(R)
Biopharmaceuticals Generics Distribution
 HSMN NewsFeed - 10 Oct 2006
Triax Pharmaceuticals Announces the Launch of MINOCIN(R) (minocycline HCl) Professional Acne Care (PAC)
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 28 Sep 2006
New Study: AVONEX(R), The Most Prescribed Multiple Sclerosis Treatment Worldwide, Demonstrates Superior Adherence
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 May 2006
Desvenlafaxine Succinate (DVS-233) Phase 3 Data Show Significant Improvement in Symptoms of Depression in Adult Patients Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2006
Medicis Announces FDA Approval of SOLODYN -- minocycline HCl, USP -- Extended Release Tablets
Biopharmaceuticals Dermatology FDA
Return to NewsFeed  

 Additional items found! 24

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 24 additional stories matching:
vertigo
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!